The FDA new drug approval process
Gifford, R.W.
Connecticut Medicine 44(5): 309-311
1980
ISSN/ISBN: 0010-6178 PMID: 7379526 Document Number: 165058
Document emailed within 1 workday
Related Documents
Cohen, M.H.; Johnson, J.R.; Pazdur, R. 2005: U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 11(1): 12-191993: FDA issues regulations on accelerated drug-approval process Clinical Pharmacy 12(4): 253-254
Wolfe, S.M. 2014: Does $760 m a year of industry funding affect the FDA's drug approval process? Bmj 349: G5012
Anderson, L.F. 1989: Cancer and AIDS groups push for changes in drug approval process Journal of the National Cancer Institute 81(11): 829-831
Fredd, S.B. 1990: The OTC drug approval process. The ACG Committee on FDA-Related Matters. American College of Gastroenterology American Journal of Gastroenterology 85(1): 12-14
Browne, T.R. 1993: Clinical trials performed for the new drug approval process in the United States: standard methods and alternative methods Epilepsy Research. Suppl 10: 31-44
Astrup, K.G.; Riis, P. 1995: Drug approval. Orientation from the drug department of the National Board of Health and Welfare and the scientific-ethical committee system Ugeskrift for Laeger 157(46): 6442-6443
Stribling, J.H. 1992: What's holding up animal drug approval? Journal of the American Veterinary Medical Association 200(12): 1806-1808
Morrow, T. 2015: A Rare Approval. FDA OKs Pediatric Cancer Drug Managed Care 24(10): 42-43
Otsuka, Y. 2012: Drug approval lag in Japan and drugs for children No to Hattatsu 44(1): 2
1991: Pre-approval inspections/investigations. Food and Drug Administration Journal of parenteral science and technology: a publication of the Parenteral Drug Association 45(1): 56-66
Kahn, L.G. 1998: Research resources for aquaculture drug development and approval Veterinary and Human Toxicology 40(Suppl 2): 41-43
Niimi, S. 2015: Development of guidance for the approval process of brand-new medical products and regenerative medicine products Kokuritsu Iyakuhin Shokuhin Eisei Kenkyujo Hokoku 133: 1-7
de Graeff PA; Hoppe 1996: The use of ambulatory blood pressure monitoring to evaluate antihypertensive drugs for drug approval Blood Pressure Monitoring 1(3): 313-315
Thomas, J.W. 1995: AHi perspectives: flexible drug labeling and its impact on the drug development process. Liability issues Journal of the American Veterinary Medical Association 207(7): 899-900; Discussion: 902-904
Apley, M.D. 1995: AHi perspectives: flexible drug labeling and its impact on the drug development process. Practical aspects of flexible labeling in feedlots Journal of the American Veterinary Medical Association 207(7): 901
Rodrigues, L.O.; Alves, T.P.; Cardoso, J.P.; Menezes, J.é C. 2006: Improving drug manufacturing with process analytical technology Idrugs: the Investigational Drugs Journal 9(1): 44-48
Sipilanyambe, N.; Simon, J.L.; Chanda, P.; Olumese, P.; Snow, R.W.; Hamer, D.H. 2008: From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia Malaria Journal 7: 25
Fibbi, G.; Serni, U.; Matucci, A.; Mannoni, A.; Pucci, M.; Anichini, E.; Del Rosso, M. 1994: Control of the chondrocyte fibrinolytic balance by the drug piroxicam: relevance to the osteoarthritic process Journal of Rheumatology 21(12): 2322-2328
Jordan, S.C.; Choi, J.; Vo, A. 2015: Strategies to Improve Novel Drug Development in Kidney Transplantation Through the Clinical Trials Process Clinical Transplants 31: 163-172